Back to Stakeholders

Helsinki University Hospital (HUS) is Finland's largest academic medical center and the clinical partner of the University of Helsinki's Neuropsychopharmacology and Neuroscience Center laboratories, which produced the landmark discovery that psychedelics directly bind the TrkB BDNF receptor with far greater affinity than conventional antidepressants. As Finland's primary academic hospital, HUS provides the clinical infrastructure for ketamine-based treatments for suicidal depression and the planned translation of Finnish psychedelic neuroscience into human trials.

Academic Research

0 papers

Published Papers

0

Trial Involvement

1

Distinct Focus Topics

0

Latest Publication

Unknown

Clinical Care Delivery Snapshot

Health Systems & Hospitals

Provider Model

Health System / Hospital Program

Organization Status

Unknown

Psychedelic Services

Unknown

Service Coverage

Global

Service Profile

Care Settings

Hospital Outpatient

Payer Models

Unknown

Non-Psychedelic Service Mix

Unknown

Visit Provider

Care Delivery Notes

Backfilled profile for existing L2 clinical care delivery stakeholder.

Quick Facts

Type
Other
HQ
Finland
Website
Visit

Sponsored Trials

1